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Chronic pancreatitis (CP) may be caused by oxidative stress. An important source of reac-
tive oxygen species (ROS) is the methylglyoxal-derived formation of advanced glycation
endproducts (AGE). Methylglyoxal is detoxified by Glyoxalase I (GLO1). A reduction in
GLO1 activity results in increased ROS. Single nucleotide polymorphisms (SNPs) of GLO1
have been linked to various inflammatory diseases. Here, we analyzed whether common
GLO1 variants are associated with alcoholic (ACP) and non-alcoholic CP (NACP).
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Methods
Using melting curve analysis, we genotyped a screening cohort of 223 ACP, 218 NACP
patients, and 328 controls for 11 tagging SNPs defined by the SNPinfo LD TAG SNP Selec-
tion tool and the functionally relevant variant rs4746. For selected variants the cohorts were
extended to up to 1,441 patient samples.
Results
In the ACP cohort, comparison of genotypes for rs1937780 between patients and controls
displayed an ambiguous result in the screening cohort (p = 0.08). However, in the extended
cohort of 1,441 patients no statistically significant association was found for the comparison
of genotypes (p = 0.11), nor in logistic regression analysis (p = 0.214, OR 1.072, 95% CI
0.961–1.196). In the NACP screening cohort SNPs rs937662, rs1699012, and rs4746 dis-
played an ambiguous result when patients were compared to controls in the recessive or
dominant model (p = 0.08, 0.08, and 0.07, respectively). Again, these associations were not
confirmed in the extended cohorts (rs937662, dominant model: p = 0.07, logistic regression:
p = 0.07, OR 1.207, 95% CI 0.985–1.480) or in the replication cohorts for rs4746 (Germany,
p = 0.42, OR 1.080, 95% CI 0.673–1.124; France, p = 0.19, OR 0.90, 95% CI 0.76–1.06;
China, p = 0.24, OR 1.18, 95% CI 0.90–1.54) and rs1699012 (Germany, Munich; p = 0.279,
OR 0.903, 95% CI 0.750–1.087).
Conclusions
Common GLO1 variants do not increase chronic pancreatitis risk.
Introduction
Chronic pancreatitis (CP) is a recurring inflammation of the pancreas with progressive fibrosis
by tissue destruction that in some patients results in exocrine and endocrine pancreatic insuffi-
ciency [1]. Several studies have identified that the underlying pathomechanisms can range
from premature intrapancreatic activation of proteases to local and systemic inflammatory
processes, which are relevant for the initiation and progression of the disease [2]. Recently, it
was demonstrated that oxidative stress (ROS) is involved in these inflammatory and fibrotic
processes [3–5]. As advanced-glycation-end products (AGE) impact on ROS, they may con-
tribute to CP development [6] as it was shown in acute pancreatitis [7].
“Dicarbonyl stress” indicates a cellular condition where α-oxoaldehyde metabolites accu-
mulate, leading to an increased modification of protein and DNA which contribute to cellular
dysfunction in ageing and disease. “Dicarbonyl stress” is mainly caused by methylglyoxal
(MGO) that is formed as a by-product in glycolysis [8], ketone body metabolism and threonine
catabolism [9–11]. MGO is highly reactive with nucleotides, phospholipids and proteins
[12,13] with the result of a rapid formation of AGE. In addition, reducing sugars like glucose
react with amino groups and trigger MGO formation and AGE generation in a non-enzymatic
protein glycation within the Maillard reaction [6]. AGE themselves induce several detrimental
processes on a cellular level and furthermore activate different signaling pathways via the
RAGE receptor. Moreover, they induce ROS and have been associated with various disease
entities [14].
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For protection on the cellular level MGO is detoxified by the Glyoxalase system. Glyoxalase
I (GLO1) catalyzes the conversion of α-oxo-aldehydes such as MGO and L-glutathione (GSH)
to form the corresponding hemithioacethal S-D-lactoylglutathione [15]. In the next step,
hydroxyacyl glutathione hydrolase (GLO2) converts S-D-Lactoylglutathione to D-lactate and
GSH. Herein, GLO1 is the rate-limiting enzyme in this series of reactions [16].
Thus far, GLO1 single nucleotide polymorphisms (SNPs) were associated with distinct
inflammatory diseases. The rs4746 (p.Ala111Glu) variant displayed a decrease of GLO1 enzy-
matic activity for the A-allele in lymphoblastoid cells of the brain [17,18]. In addition, rs4746
has been linked to diabetes [19], atherosclerosis [20], chronic renal failure [21], vascular dis-
eases [22,23], neuropsychiatric disorders [24,25], and different cancer types [26–29]. More-
over, rs1130534 (c.372A>T, p.Gly124 = ) and rs1049346 were correlated with lower enzyme
activity, but did not associate with vascular complications in diabetes mellitus [30].
In conclusion, GLO1 variants with a diminished GLO1 activity cause increased MGO levels
and consecutive ROS generation. Therefore, we reasoned that GLO1 SNPs contribute to the
development of CP and investigated whether genetic variants in GLO1 are associated with
alcoholic CP (ACP) or non-alcoholic CP (NACP).
Material and methods
Patients and controls
The study was approved by the medical ethical review committee of the Martin-Luther-Uni-
versity of Halle-Wittenberg (Medical ethical committee, University Halle-Wittenberg, Medical
Faculty, Bearbeitungsnummer 2015–106, date: 22.01.2016, title: “Erforschung molekulargen-
etischer Ursachen von Pankreaserkrankungen”). All patients gave written informed consent.
The diagnosis of CP was based on two or more of the following findings: history of recurrent
acute pancreatitis or recurrent or persisting abdominal pain typical for CP, pancreatic calcifi-
cations and/or pancreatic ductal irregularities indicated by computed tomography imaging,
magnetic resonance imaging, endoscopic retrograde pancreaticography or (endo)sonography
of the pancreas and/or the diagnosis of exocrine pancreatic insufficiency [31].
ACP was diagnosed in patients with a history of chronic alcohol intake (> 80 g per day for
males or>60 g per day for females) for more than 2 years. NACP was diagnosed in the absence
of known precipitating factors as alcohol consumption and/or smoking. Patients with a posi-
tive family history were included in the NACP group. The data on past ethanol consumption
and the clinical presentation were based on research records and/or physician’s history and/or
completion of a detailed questionnaire by the patient.
Patients and Controls were recruited throughout Germany and in the European centres in
The Netherlands, Romania, Poland, Italy, and Hungary. Controls were blood donors and
healthy volunteers as described in our former publications [32].
In the screening cohort we investigated 223 ACP, 218 NACP patients, and 328 controls for
12 common GLO1 SNPs with a minor allele frequency of a least 5%. Variants with nominal
significance according to uncorrected p-values (rs1699012, rs937662, rs4746, and rs1937780)
were analyzed in further subjects (extended cohorts). In addition, we screened European ACP
cohorts for rs1937780 and an additional German, French, and Chinese NACP cohort for
rs4746 and an independent German NACP cohort for rs1699012 (see flow chart in Fig 1). For
a detailed description of the screening cohort and the extended cohorts see Table 1.
Selection of tagging SNPs in the GLO1 locus
We selected 11 tagging SNPs in the GLO1 locus using the SNPinfo LD TAG SNP Selection
tool (LD map Figure A in S1 File). For this purpose we used an LD threshold of 0.8, a
GLO1 SNPs in chronic pancreatitis
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minimum of one SNP tagged, a minimum of 5 valid genotypes to calculate LD in populations
with European ancestry (CEU) and extended the region of interest by 10.000 bp in the 5’-
region and the 3’-region. In addition, we analyzed SNP rs4746 that was described to be func-
tionally relevant [17,18]. The other functionally relevant SNPs rs1049346 and rs1130534 were
tagged by rs1621788 and rs13212218, respectively. Details on the selected SNPs are summa-
rized in Table A in S1 File.
DNA extraction and SNP genotyping
DNA was isolated from EDTA blood using a commercial system (QIAamp Blood DNA Mini
Kit; Qiagen, Hilden, Germany). Polymerase chain reaction (PCR) was conducted using One-
Taq1 2X Master Mix (NEB) with 200 μM dNTPs, 1.8 mM MgCl2 and 0.1 μM forward primer
as well as 0.1 μM reverse primer (0.4 μM forward primer for rs3778443 and rs17544798;
0.2 μM reverse primer for rs4746) in a total volume of 25 μl. Cycle conditions were an initial
denaturation at 95˚C for 5 minutes followed by 45 cycles of 20 seconds denaturation at 95˚C,
Fig 1. Flowchart of patients analyzed in this study. Note that the extended cohorts comprise the screening cohort and novel patients for all German patients (SNPs
rs937662, rs1937780, and rs4746). For rs1699012 the numbers summarize the extended with the replication cohort from Munich. The European cohorts (rs1937780) and
the German, French, and Chinese replication cohorts for rs4746 are additional patients.
https://doi.org/10.1371/journal.pone.0222927.g001
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40 seconds annealing (Table B in S1 File), 90 seconds primer extension at 72˚C followed by
final extension for 5 minutes at 72˚C in an automated thermal cycler. Primers and probes
(Table B in S1 File) were synthesized by TIB Molbiol (Berlin, Germany). Genotyping was per-
formed using the LightCycler4801 system (Roche Diagnostics).
Probe oligomers were diluted in H2O to a concentration of 200 nM. For genotyping we
used the PCR products from standard PCR (see above) with 50 nM (final) of probe oligomers
followed by melting curve analysis with the following protocol: 95˚C for 60 seconds, 40˚C for
60 seconds, continuous increase to 70˚C with various ramp rates (0.29˚C/s rs12198212 and
rs1621788, 0.14˚C/s rs17544798, rs132212218 and rs937662, 0.19˚C/s for the other seven
SNPs). Call rates for all SNPs were> 95%. For quality control 2.6% of all samples were geno-
typed in duplicates blinded to the investigator. Resulting concordance rate was 99.7%.
Statistical analysis
Quality of SNP genotypes was assessed by study-wise call rate and exact test for Hardy-Wein-
berg disequilibrium (HWE) in patients and controls. We compared the results for genotype
Table 1. Description of the cohorts included in the analysis.
Cohort type No. Age (mean) Age (median) Age range Male sex
Screening cohort (11 tagging SNPs + rs4746)
Controls 328 63.9 63 60–70 49.4%
ACP 223 49.9 50 21–79 88.8%
NACP 218 39.6 39 5–80 56.2%
Screening cohort extended with additional German patients (rs1699012 and rs937662) and replication cohort from Germany (rs1699012)
Controls 625 60.8 63 20–70 48.8%
ACP 451 49.9 50 21–79 82.3%
NACP 314 36.6 35 3–80 53.2%
NACP (Munich) � 427 19.2 14 0–71 51.1%
Screening cohort extended with additional German patients (rs4746)
Controls 581 63.8 63 60–70 49.9%
ACP (German) 230 46.4 46 21–79 89%
NACP (German) 288 37.5 38 3–80 56.2%
Replication cohorts Germany and France (rs4746)
Controls (German) 581 63.8 63 60–70 49.9%
NACP (German) 450 16.9 13 0–61 46.4%
Controls (French) 1049 45.7 40 24–63 56.2%
NACP (French) 767 39.7 35 4–93 56.0%
Controls (China) 504 41.0 41 18–62 66.9%
NACP (China) 464 45.0 46 5–91 71.6%
Screening cohort extended with additional German patients (rs1937780)
Controls 1474 46.1 47 18–70 49.2%
ACP 872 44.7 45 14–85 87.3%
NACP 285 48.8 59 3–80 57.6%
Screening cohort extended with additional European and German patients (rs1937780)
Controls 2306 47.8 48 18–99 48.1%
ACP 1441 44.7 45 14–98 85.0%
Note: The extended cohorts comprise the initial screening cohort and additional patients.
�Independent German replication cohort from Munich for rs1699012. Abbreviations: No., number of individuals; ACP, alcoholic chronic pancreatitis; NACP, non-
alcoholic chronic pancreatitis.
https://doi.org/10.1371/journal.pone.0222927.t001
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frequencies of the different polymorphisms between patient cohorts and control populations
with the Chi-square test and logistic binary regression. All other models (dominant, recessive,
allele frequencies) were computed by using two-tailed Fisher’s Exact test. P-values were calcu-
lated using IBM SPSS Statistics 25 and GraphPad Prism 5. A p-value of less than 0.05 was con-
sidered to be significant. When a significant or nominal significant association was found, at
least an extended or one replication cohort was screened.
Results
No study-wide significant association of GLO1 SNPs with ACP
We identified no significant association in logistic regression analysis and no significant differ-
ence in the genotype distribution in the ACP screening cohort compared to controls (Table 2
and Table C in S1 File). As for rs937662 the HWE was nominal significant in our controls
(p = 0.047) and for both rs937662 and rs1699012 nominal significant results were observed in
the NACP screening cohort in the dominant or recessive model (p = 0.08, respectively) we
extended our analysis in the ACP cohort to 430 and 447 patients. Here, we found no associa-
tion for both SNPs and no deviation from HWE for rs937662 in the controls (p = 0.38; con-
trols) (Table 3). Furthermore, genotype data of rs1937780 displayed a borderline significance
in the screening cohort (p = 0.08). Again, we extended our investigated groups and analysed
rs1937780 in a further German ACP cohort and additional European ACP patients from The
Netherlands, Hungary, Italy, Romania and Poland. In the German cohort (n = 872) compared
to controls (n = 1,474) the association was statistically significant (p = 0.003) as the genotype
distribution between ACP patients and controls differed (GG: 40.0% vs. 33.1%; GA 45.9% vs.
51.6%; AA 14.1% vs. 15.3%) (Table D in S1 File). Of note, there was a deviation from HWE in
the controls of the extended German cohort (p = 0.01). However, we did not find a significant
association in logistic regression analysis (p = 0.134, odds ratio (OR) OR 1.117, 95% confi-
dence interval (95% CI) 0.966–1.290) for this cohort. Otherwise, in the overall cohort of Euro-
pean ACP patients and controls we found no significant association in logistic regression
analysis either (p = 0.214, OR 1.075, 95% CI 0.961–1.196) (Table E in S1 File). This result was
Table 2. Binary logistic regression results of the GLO1 single nucleotide polymorphisms in patients with alcoholic and non-alcoholic chronic pancreatitis with
covariate sex.
SNP ACP NACP
p-value OR 95% CI p-value OR 95% CI
rs2736655 0.261 0.806 0.554–1.174 0.292 0.838 0.603–1.164
rs9380765 0.345 1.143 0.866–1.507 0.077 1.374 0.966–1.953
rs13212218 0.936 0.983 0.642–1.505 0.578 0.898 0.614–1.313
rs937662 0.621 0.952 0.783–1.157 0.070 1.207 0.985–1.480
rs1621788 0.548 1.085 0.831–1.417 0.526 1.083 0.847–1.384
rs12198212 0.483 1.116 0.822–1.514 0.216 1.196 0.901–1.589
rs1699012 0.508 0.935 0.767–1.140 0.009 0.763 0.623–0.933
rs1616723 0.639 1.127 0.684–1.855 0.962 1.012 0.630–1.623
rs1937780 0.134 1.117 0.966–1.290 0.112 1.176 0.963–1.436
rs3778443 0.992 1.003 0.564–1.783 0.323 1.348 0.746–2.438
rs4746 0.918 0.987 0.770–1.264 0.008 1.342 1.080–1.669
rs17544798 0.133 0.752 0.518–1.091 0.786 1.053 0.727–1.525
Abbreviations: SNP, single-nucleotide polymorphism; OR, Odds ratio; CI, confidence interval; ACP, alcoholic chronic pancreatitis; NACP, non-alcoholic chronic
pancreatitis.
https://doi.org/10.1371/journal.pone.0222927.t002
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confirmed for the corresponding genotype data and none of the five replication cohorts dem-
onstrated a statistically significant association in the different genetic models used for compu-
tations (Table 4 and Tables D and E in S1 File). Except for the named SNPs and SNP
rs2736655 (ACP patients p = 0.026), all SNPs corresponded to the HWE.
Table 3. Data of the analysed GLO1 SNPs in patients with alcoholic chronic pancreatitis (ACP) and controls. For
the calculations different genetic models were used.
SNP/Genetic model for calculation p-value OR 95% CI
rs2736655 G/A 0.36 0.849 0.613–1.176
GG + GA/AA 0.19 0.778 0.538–1.124
GG/GA + AA 0.48 2.034 0.407–10.18
rs9380765 A/G 0.61 1.074 0.838–1.377
AA + AG/GG 0.32 1.218 0.828–1.794
AA/AG + GG 0.91 0.971 0.627–1.505
rs13212218 G/A 1.00 0.991 0.675–1.453
GG + GA/AA 0.83 0.944 0.623–1.430
GG/GA + AA 0.65 2.777 0.308–25.03
rs937662 C/T 0.99 0.995 0.834–1.187
CC + CT/TT 0.80 0.950 0.683–1.321
CC/ CT + TT 0.89 1.021 0.787–1.324
rs1621788 A/G 0.54 1.087 0.853–1.385
AA + AG/GG 0.76 1.089 0.724–1.639
AA/AG + GG 0.49 1.143 0.778–1.679
rs12198212 T/A 0.37 1.136 0.864–1.494
TT + TA/AA 0.87 1.108 0.567–2.164
TT/TA + AA 0.33 1.192 0.845–1.682
rs1699012 A/G 0.32 0.909 0.759–1.089
AA + AG/GG 0.33 0.878 0.680–1.133
AA/AG + GG 0.65 0.942 0.730–1.215
rs1616723 T/C 0.81 0.942 0.590–1.503
TT + CT/CC 1.00 1.390 0.125–15.44
TT/CT + CC 0.79 0.921 0.561–1.512
rs1937780 G/A 0.61 1.073 0.834–1.381
GG + GA/AA 0.30 0.763 0.466–1.251
GG/GA + AA 0.15 1.324 0.927–1.890
rs3778443 G/A 0.49 0.813 0.479–1.381
GG + GA/AA 1.00 1.952 0.079–48.18
GG/GA + AA 0.39 0.776 0.447–1.344
rs4746 T/G 0.54 1.072 0.862–1.333
TT + TG/GG 0.92 1.045 0.705–1.550
TT/TG + GG 0.45 1.137 0.818–1.581
rs17544798 A/T 0.20 0.794 0.569–1.107
AA + AT/TT 0.12 0.380 0.110–1.314
AA/AT + TT 0.33 0.819 0.561–1.194
The different models comprise (order from top to bottom), allele frequencies, the dominant and the recessive model
for computations. The number of patients and the genotype distribution of each variant are summarized in Table C
in S1 File. Note: For rs937662 and rs1699012 the extended German cohorts have been used for computations.
Calculations were performed using the Fisher’s exact test. Abbreviations: OR = odds ratio, 95% CI = 95% confidence
interval.
https://doi.org/10.1371/journal.pone.0222927.t003
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No study-wide significant association of GLO1 SNPs with NACP
In the screening cohort the SNPs rs937662, rs1699012, and rs4746 displayed a nominal signifi-
cant difference in the recessive or dominant model (p = 0.08, 0.08, and 0.07, respectively)
(Table 5). Otherwise, no differences in the genotype distributions were observed (Table F in
S1 File). Furthermore, we detected a significant association for SNP rs1699012 (p = 0.009, OR
0.763, 95% CI 0.623–0.933) and rs4746 (p = 0.008, OR 1.342, 95% CI 1.080–1.669) in logistic
regression analysis (Table 2). To elucidate a potential association, we extended the German
NACP cohort and found no statistically significant association of the genotype distribution for
rs937662 (p = 0.15), whereas rs1699012 and rs4746 still displayed a significant association com-
pared to controls (p = 0.02 and p = 0.008, respectively) (Table G in S1 File). Therefore, we
investigated rs4746 in an independent German (n = 450, patients; n = 581, controls), French
(n = 767, patients; n = 1,049, controls), and Chinese (n = 928, patients; n = 1,008, controls)
NACP cohort. Here, no association was found in all three replication cohorts (Table 6; for
genotype distribution see Table G in S1 File). Finally, for SNP rs1699012 we observed no sig-
nificant association (p = 0.279, OR 0.903, 95% CI 0.750–1.087) in an independent German
NACP cohort of 427 patients in logistic regression analysis (for different genetic models see
Table 6). For the rare SNP rs3778443 we observed a significant HWE (p = 0.002).
Discussion
There is a biological plausibility that GLO1 is relevant in inflammatory processes and as such
for the development of CP, although conflicting results have been reported in other diseases
Table 4. Data of the European alcoholic chronic pancreatitis (ACP) replication cohorts for rs1937780 in comparison to controls. Calculations were performed with
different genetic models.
SNP/Genetic model for calculations p-value OR 95% CI
rs1937780
(Germany)
G/A 0.006 1.187 1.051–1.340
GG + GA/AA 0.46 1.103 0.870–1.399
GG/GA + AA 0.0009 1.348 1.133–1.604
rs1937780
(Hungary)
G/A 0.82 0.939 0.601–1.465
GG + GA/AA 1.00 1.141 0.463–2.811
GG/GA + AA 0.63 0.815 0.423–1.571
rs1937780
(The Netherlands)
G/A 0.81 0.968 0.764–1.226
GG + GA/AA 0.73 1.112 0.700–1.766
GG/GA + AA 0.5 0.887 0.636–1.238
rs1937780
(Romania)
G/A 0.45 1.293 0.717–2.333
GG + GA/AA 0.34 2.121 0.513–8.767
GG/GA + AA 0.66 1.286 0.539–3.068
rs1937780
(Poland)
G/A 0.78 1.095 0.622–1.927
GG + GA/AA 0.42 1.882 0.582–6.088
GG/GA + AA 0.84 0.855 0.376–1.946
rs1937780
(Italy)
G/A 0.49 1.141 0.815–1.599
GG + GA/AA 0.43 1.298 0.713–2.364
GG/GA+AA 0.70 1.126 0.673–1.883
rs1937780
(all)
G/A 0.05 1.103 1.003–1.214
GG + GA/AA 0.05 1.151 1.004–1.319
GG/GA + AA 0.24 1.122 0.931–1.351
The different models comprise (order from top to bottom), allele frequencies, the dominant and the recessive model for computations. The number of patients and the
genotype distribution of each variant are summarized in Table D in S1 File. Note, the German cohort used here comprises the screening cohort and further samples.
Calculations were performed using the Fisher’s exact test. Abbreviations: OR = odds ratio, 95% CI = 95% confidence interval.
https://doi.org/10.1371/journal.pone.0222927.t004
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thus far. In this work, we investigated a potential genetic association of GLO1 variants with
ACP and NACP. We failed to identify an association between CP and one functionally relevant
variant and 11 tagging SNPs covering the GLO1 locus.
In our German ACP patients (total cohort) rs1937780 genotypes differed significantly
between patients and controls (p = 0.003) and significance was also observed in the dominant
model. Contrary, we found neither an association nor a comparable trend in the distinct
Table 5. Data of the analysed GLO1 SNPs in patients with non-alcoholic chronic pancreatitis (NACP) and controls. For the calculations different genetic models
were used.
SNP/Genetic model for calculations p-value OR 95% CI
rs2736655 G/A 0.35 0.853 0.614–1.184
GG + GA/AA 0.11 0.423 0.150–1.218
GG/GA + AA 0.63 0.909 0.624–1.324
rs9380765 A/G 0.31 0.874 0.682–1.119
AA + AG/GG 0.44 0.844 0.551–1.294
AA/AG + GG 0.35 0.807 0.536.1.217
rs13212218 G/A 0.56 0.889 0.610–1.295
GG + GA/AA 1.00 0.900 0.199–4.065
GG/GA + AA 0.53 0.875 0.579–1.322
rs937662 C/T 0.16 1.201 0.935–1.542
CC + CT/TT 0.71 1.115 0.679–1.834
CC/ CT + TT 0.08 1.388 0.967–1.993
rs1621788 A/G 0.62 1.070 0.838–1.366
AA + AG/GG 0.84 1.057 0.702–1.592
AA/AG + GG 0.55 1.128 0.766–1.663
rs12198212 T/A 0.24 1.182 0.898–1.563
TT + TA/AA 0.48 1.385 0.677–2.833
TT/TA + AA 0.29 1.207 0.854–1.705
rs1699012 A/G 0.12 0.813 0.631–1.048
AA + AG/GG 0.08 0.650 0.402–1.051
AA/AG + GG 0.37 0.842 0.589–1.204
rs1616723 T/C 0.91 0.974 0.608–1.560
TT + CT/CC 1.00 1.390 0.125–15.44
TT/CT + CC 0.90 0.956 0.581–1.575
rs1937780 G/A 0.32 1.145 0.882–1.486
GG + GA/AA 0.39 1.336 0.749–2.380
GG/GA + AA 0.45 1.161 0.803–1.680
rs3778443 G/A 0.37 1.341 0.729–2.470
GG + GA/AA 0.56 0.319 0.029–3.541
GG/GA + AA 0.27 1.519 0.790–2.920
rs4746 T/G 0.17 1.194 0.931–1.531
TT + TG/GG 0.82 1.076 0.680–1.702
TT/TG + GG 0.07 1.415 0.978–2.047
rs17544798 A/T 0.17 1.194 0.931–1.531
AA + AT/TT 1.00 1.329 0.241–7.324
AA/AT + TT 0.77 1.066 0.719–1.579
The different models comprise (order from top to bottom), allele frequencies, the dominant and the recessive model for computations. The number of patients and the
genotype distribution of each variant are summarized in Table F in S1 File. Calculations were performed using the Fisher’s exact test. Abbreviations: OR = odds ratio,
95% CI = 95% confidence interval.
https://doi.org/10.1371/journal.pone.0222927.t005
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European cohorts. The same variant has recently been investigated in pancreatic cancer
patients and an association was absent [33]. As functional consequences of this variant are
unknown and overall genetic data are statistically not significant, it is unlikely that rs1937780
plays a prominent role in CP development.
In the NACP cohort the three variants rs937662, rs1699012, and rs4746 showed borderline
significant results in distinct analysis models that, however, were not confirmed in the
extended or replication cohorts. For the variants rs937662 and rs1699012 no prior clinical rele-
vance has been reported and therefore an association with CP is again unlikely. Contrary,
rs4746 was associated with a wide spectrum of disorders ranging from diabetes [19], athero-
sclerosis [20], chronic renal failure [21], vascular diseases [22,34], neuropsychiatric disorders
[24,25], and even to cancer [26–29]. In our work the borderline significance of the screening
cohort was disproved in three large NACP cohorts from Germany, France, and China. As
such, although, a functional relevance for this variant has been reported, our data show no
association with CP.
We investigated cohorts with a reasonable number of patients and extended these cohorts
whenever statistically or nominal significant results were obtained. Therefore, a prominent
disease association of GLO1 variants with CP can be ruled out with high certainty. Neverthe-
less, our approach is not capable of identifying rare associating variants. We therefore analyzed
Table 6. Data of the replication cohorts of GLO1 SNPs rs937662, rs1699012, rs4746 in patients with non-alcoholic
chronic pancreatitis (NACP) and controls. For computations different genetic models were used.
SNP/Genetic model for calculations p-value OR 95% CI
rs937662 C/T 0.06 1.212 0.994–1.477
CC + CT/ TT 0.25 1.279 0.865–1.892
CC/CT + TT 0.07 1.299 0.980–1.722
rs1699012 A/G 0.01 0.766 0.627–0.936
AA + AG/GG 0.01 0.607 0.413–0.893
AA/AG + GG 0.08 0.768 0.579–1.018
rs1699012
(Germany replication)
A/G 0.31 0.907 0.755–1.089
AA + AG/GG 0.77 0.938 0.640–1.375
AA/AG + GG 0.22 0.854 0.664–1.099
rs4746
(Germany)
T/G 0.003 1.360 1.108–1.669
TT + TG/GG 0.09 1.407 0.952–2.079
TT/TG + GG 0.004 1.571 1.168–2.112
rs4746
(Germany replication)
T/G 0.34 1.093 0.917–1.303
TT + TG/GG 0.63 1.097 0.797–1.510
TT/TG + GG 0.31 1.152 0.883–1.503
rs4746
(France)
T/G 0.11 1.117 0.979–1.276
TT + TG/GG 0.06 1.262 0.998–1.596
TT/TG + GG 0.44 1.087 0.888–1.331
rs4746
(China)
T/G 0.27 1.175 0.897–1.539
TT + TG/GG 0.81 0.815 0.312–2.132
TT/TG + GG 0.25 0.837 0.621–1.129
The different models comprise (order from top to bottom), allele frequencies, the dominant and the recessive model
for computations. The number of patients and the genotype distribution of each variant are summarized in Table G
in S1 File. Note, for rs937662, rs1699012, and rs4746 the extended German cohorts comprise the screening cohort
and further German samples. For rs1699012 the replication cohort from Munich is displayed. Calculations were
performed using the Fisher’s exact test. Abbreviations: OR = odds ratio, 95% CI = 95% confidence interval.
https://doi.org/10.1371/journal.pone.0222927.t006
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whole exome sequencing data from an ongoing project but did not identify rare variants
enriched in our NACP patients (unpublished data). Nonetheless, our study is limited in its
restriction to a Caucasian (German) cohort as only one SNP was analyzed in an Asian replica-
tion cohort and therefore we may have missed specific associations in other ethnicities.
In summary, we performed a comprehensive investigation of GLO1 variants and did not
demonstrate a prominent role for CP development in alcoholic and the non-alcoholic etiolo-
gies of the disease.
Supporting information
S1 File. Figure A. Linkage disequilibrium figure of the GLO1 locus generated by the
SNPinfo LD TAG SNP Selection tool.
To generate the linkage disequilibrium (LD) figure, the SNPinfo LD TAG SNP Selection tool
(https://snpinfo.niehs.nih.gov/snpinfo/snptag.html) with the following parameters was
applied: LD threshold of 0.8; a minimum of one SNP tagged; a minimum of 5 valid genotypes
to calculate LD in populations with European ancestry (CEU); integrated region with 10.000
bp in the 5’-region and the 3’-region of GLO1. Abbreviations: SNP, single nucleotide polymor-
phism; LD, linkage disequilibrium; CEU, Northern Europeans from Utah. For the following
SNPs we used tagging SNPs in our study: rs10484854 was tagged by rs12198212; rs1781735 by
rs1621788; rs6458064 by rs937662; and rs9394523 by rs13212218. As demonstrated in the fig-
ure the tagging SNPs represented the depicted haplotypes. In Table A in S1 File the informa-
tion on the SNPs selected according to the published literature and by SNPinfo is summarized.
Table A. Overview of screened GLO1 SNPs that were identified by SNPinfo or by a litera-
ture research.
We used the SNPinfo LD TAG SNP Selection tool to identify SNPs in the GLO1 locus that
cover the haplotypes of the gene. As several variants have been reported in the literature, we
included these using tagging SNPs, where possible. The corresponding literature for the
screened SNPs is indicated in brackets. For rs4746 several studies reported associations and
functional data are available in addition. � These SNPs have been tagged by the screened SNP
rs1616723, rs9380765, rs13212218, and rs1621788 respectively.
Table B. Polymerase chain reaction (PCR) primers and probes for melting curve analysis of all
GLO1 SNPs. Abbreviations: fw, forward; rv, reverse; XI, internal dye modified base; LC610, 5´-
LightCycler Red 610; LC640 (sensor probe), LightCycler Red 640 (sensor probe); FL, 3’-Fluo-
rescein labelling (anchor probe); PH, 3´-phosphate.
Table C. Genotype data of the analysed GLO1 SNPs in patients with alcoholic chronic pan-
creatitis (ACP) and controls.
Note: For rs937662 and rs1699012 the extended German cohorts are shown. Calculations were
performed using the Chi-square test (two-sided). Abbreviations: Contr. = controls, Pat. =
patients.
Table D. Genotype data of the GLO1 SNP rs1937780 in patients with alcoholic chronic
pancreatitis in European cohorts including Germany. Note: The German cohort comprises
the screening cohort and additional samples. Calculations were performed using the Chi-
square test (two-sided). Abbreviations: Contr. = controls, Pat. = patients.
Table E. Results of logistic regression with covariate gender for the GLO1 SNP rs1937780
in patients with alcoholic chronic pancreatitis in European cohorts including Germany.
Note: The German cohort comprises the screening cohort and additional samples. Calcula-
tions were performed using logistic regression. Abbreviations: OR, Odds ratio; CI, confidence
interval; ACP, alcoholic chronic pancreatitis.
Table F. Genotype data of the analysed GLO1 SNPs in German patients with non-alcoholic
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chronic pancreatitis (NACP) and controls.
Calculations were performed using the Chi-square test (two-sided). Abbreviations: Contr. =
controls, Pat. = patients.
Table G. Genotype data of the analysed GLO1 SNPs rs937662, rs1699012, rs4746 in the
extended NACP cohorts.
Note: For rs937662, rs1699012, and rs4746 the extended German cohorts comprise the screen-
ing cohort and additional German samples. Calculations were performed using the Chi-square
test (two-sided). Abbreviations: Contr. = controls, Pat. = patients. kNACP replication cohort
and controls from Germany. $ Independent NACP replication cohort from Munich. § NACP
cohort and controls from France. € NACP cohort and controls from China.
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